^
Association details:
Biomarker:No biomarker
Cancer:Gastroesophageal Junction Adenocarcinoma
Drug:Bavencio (avelumab) (PD-L1 inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: B - Late Trials
Title:

Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100

Published date:
11/16/2020
Excerpt:
JAVELIN Gastric 100 did not demonstrate superior OS with avelumab maintenance versus continued chemotherapy in patients with advanced GC or GEJC overall or in a prespecified PD-L1–positive population.
DOI:
10.1200/JCO.20.00892